None of the studies assessed the time-dependent impact of TNF-α inhibitors on the lipid profile of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and rheumatoid arthritis (RA) patients as a group. This evidence concerns the gene TNF and ankylosing spondylitis.